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What Are We Looking for?*E. Murat Tuzcu, MD,y Samir R. Kapadia, MDzT ranscatheter aortic valve replacement (TAVR)is an established treatment for severe symp-tomatic aortic stenosis patients who are not
suitable or are at high risk for surgical aortic valve
replacement (SAVR) (1–3). Several ongoing studies
are exploring its role in lower risk patients (4).
The data that secured a place for TAVR among our stan-
dard armamentarium came from the ﬁrst-generation
balloon-expandable valves (BEV) and self-expanding
valves (SEV). Although a decade of work has proved
that TAVR is a safe and effective procedure even
in very sick patients, it has some shortcomings. Para-
valvular aortic leak (PVL), the inability to change the
position of the implanted prosthesis, the need for a
permanent pacemaker, and stroke were commonly
encountered challenges, among other less frequent
issues such as coronary obstruction and annular
rupture.SEE PAGE 68Investigators have focused on improving some of
these shortcomings by device innovations and proper
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Interventions reports the initial experience with a
second-generation TAVR device that was designed to
reduce PVL. Investigators attained a 30-day mortality
of 1% and a 1-year mortality of only 10%, with a 1-year
stroke-free survival of 86% in high-risk symptomatic
severe aortic stenosis patients in their initial experi-
ence with this device. Based on this study, the Direct
Flow Medical (DFM) valve appears to reduce moder-
ate and severe as well as mild PVL substantially.
Reduction in mild PVL is particularly important
because moderate and severe PVL are rare in the
competitive space of the newer generation valves.
The DFM valve is neither a BEV nor a SEV. It is a
mechanically expandable valve that can be fully
repositioned and evaluated before permanent im-
plantation. The valve has a unique design to achieve
complete sealing at the annular level, minimizing PVL
formation. In this study, the investigators show that
the valve can be deployed successfully in a majority
of patients, with good hemodynamics and safety.
Like several newer valves, the moderate paravalvular
leak (PVL) rate is low: at 30 days, only 1 patient had
moderate PVL. Although moderate and severe PVL
have been associated with increased mortality and
heart failure admissions after TAVR (7), the impact of
mild PVL on clinical outcomes is controversial (8).
Possible explanations for inconsistencies among the
studies exploring the impact of mild PVL on mortality
include 1) inaccuracy in the diagnosis of mild PVL, 2)
frequent type II errors due to small study pop-
ulations, and 3) other comorbidities in high-risk pa-
tients potentially masking the adverse effects of mild
PVL. As TAVR indications expand for lower risk pa-
tients, elimination of even mild PVL may become
necessary to have excellent long-term outcomes.
On the other extreme, patients with severe left ven-
tricular (LV) dysfunction may also beneﬁt from
elimination of PVL because even mild PVL may be
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77detrimental in these patients. An advantage of the
DFM valve that is similar to another new generation
valve (e.g., the Lotus valve) is that it is completely
recaptureable and repositionable. This capability
provides an opportunity to the operator to reduce
the mild PVL rates even further.
In the study by Lefèvre et al. (6), the permanent
pacemaker (PPM) implantation rate after DFM valve
implantation is higher than with ﬁrst-generation BEV
and lower than SEV. It is difﬁcult to compare the PPM
rates of the new-generation transcatheter valves
because of the small numbers in most studies. The
impact of PPM implantation on clinical outcomes
after TAVR is a subject of debate. PPM implantation
was not associated with increased mortality in early
TAVR studies (9). More recent studies show that LV
function recovery may be impacted negatively by
PPM implantation. Data on heart failure admission,
sudden cardiac death, and complications from PPM
implantation remain scarce (10). Beyond the clinical
implications, the PPM rate is also important due to
increased cost. The need for PPM implantation has
been associated with self-expanding valves, the
deployment depth of certain devices, the device size
in relation to the annular size, patient age, and pre-
existing conduction disturbances to name a few. It
appears that some modiﬁcations that decrease PVL
may negatively impact the PPM rate. However, the
DFM valve in this small study was not associated with
a signiﬁcantly increase need for PPM despite a
marked decrease in PVL. Similar ﬁndings have been
reported from small early experience from EVOLUTE
R transcatheter aortic valve.
TAVR provides slightly better hemodynamics
compared with SAVR in a number of comparative
studies. Although the difference in transvalvular
gradient is small between TAVR and SAVR, it
may amount to an important beneﬁt, especially for
patients with small annulus sizes. There is someTABLE 1 Available Data on Selected Second-Generation Valves
Valve
30 Days
Patients
(n)
Mortality
(%)
All Strokes
(%)
PVL (%)
(None, Mild,
Moderate, Severe
S3 (12) 583 2.2 1.5 64/33/2.5/0
DFM (6) 100 1.0 6.0 79/20/1.2/0
Evolute R (13) 60 0 0 33/64/3/0
Lotus (14) 120 4.4 5.9 83/16/1/0
Portico (15) 102 2.9 3.9 15/73/3/0
S3 and Evolute R have been recently approved in the United States. Direct Flow Medical (
Association approval.
PPM ¼ permanent pacemaker; PVL ¼ paravalvular aortic leak.evidence that even moderate patient-prosthesis
mismatch (effective oriﬁce area <0.85 cm2/m2) can
lead to increased mortality with hazard ratio of
1.19 (11). Mean transvalvular gradients after DFM
valve implantation appear to be numerically higher
compared with those reported in other studies
(Table 1). Comparisons between different valve types
are limited by the fact that there are no studies that
compare one valve with another directly. Whether
the gradients are any different in a particular valve
compared with others and whether particular
anatomic characteristics favor one valve over the
other are debatable. The relative weakness of the
inter-ring structure of the DFM valve particularly in
patients with severe and bulky calciﬁcations or
the presence of a ventricular ring in very small
LVOT (left ventricular outﬂow tract) are proposed as
potential mechanisms for somewhat higher trans-
prosthetic gradients. Proper patient selection and
adequate pre-dilation of the native stenotic valve
frequently result in optimum gradients. Recently,
intra-procedural post-deployment balloon dilation
has been proposed by some operators as an effective
technique when optimization of the transvalvular
gradients is needed.
The stroke rate in this study was numerically
higher compared with other valves. However, this
was a small study, so the exact risk of stroke is
difﬁcult to determine. Whether repositioning or
manipulation in the aortic root increases the risk of
neurologic complications remains uncertain. Stroke
prevention is an evolving ﬁeld, and different emboli
prevention devices are being tested in clinical trials
for this purpose.
There are several important lessons to be learned
from the experience of evaluating new transcatheter
valves. Proper imaging and patient selection are of
paramount importance for the short- and long-term
success of TAVR with any given valve. Precise1 Year
)
PPM
(%)
Post-Gradient
Mean
(mm Hg)
Mortality
(%)
Stroke
(%)
PVL (%)
(None, Mild,
Moderate, Severe)
PPM
(%)
Post-Gradient
Mean
(mm Hg)
13 11.1 14.4 4.3 68/29/2.7/0 16.9 11.3
17 12.6 10.0 9.0 68/32/0/0 20.0 12.2
11.7 8.1 6.7 3.4 62/34/4/0 15.2 7.5
28.6 11.5 10.9 9.5 89/11/0/0 32.2 12.6
9.8 8.7 7.8 5.9 7/87/0/0 10.8 9.9
DFM), Portico, and Lotus valves are undergoing randomized pivotal trial in the United States for U.S. Food and Drug
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78measurement of annulus and subannular space
(landing zone for the ventricular ring) is critical for the
DFM valve implantation. Similarly, because the inter-
ring space is a closed tube, special attention to the
coronary height and sinus width measurements is a
prerequisite in order to prevent coronary occlusions.
No such complications were reported in this study,
which highlights the importance of proper patient
selection and pre-procedural planning. As expected
from the design of the valve, there was no annular
rupture or trauma to LVOT or aorta in this study.
The purpose of this study was to demonstrate the
safety of the device and the feasibility of implanta-
tion without PVL. The investigators demonstrated
that the device is safe and effective and that favorable
outcomes are maintained for 1 year and more. How-
ever, how the DFM valve compares with other
approved devices remains unanswered and will need
a direct comparison trial. Although the investigators
presented patient characteristics of the CoreValve
and PARTNER (Placement of AoRtic TraNscathetER
Valves) trials for comparison, this study in no way
provides comparative data. The patient populationof current study is quite different from those of
the initial TAVR studies. Appropriately, the U.S.
Food and Drug Administration is requiring head-
to-head comparison of newer valves with commer-
cially available valves for U.S. approval. Mortality,
stroke, PVL, PPM, and hemodynamics should be
compared in these trials, with the potential to col-
lect long-term durability data. Without randomized
device-to-device comparative trials, it impossible
to determine from single-arm registries whether
differences in outcomes are the result of different
patient characteristics or distinguishing properties
of the devices.
In summary, the investigators should be congrat-
ulated for providing thorough results from a new
generation valve that shows great promise. Future
pivotal trials with a comparator arm will provide data
for valve selection in different patient populations
as the TAVR ﬁeld matures.
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